ORIENT BIO Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jae-Jin Chang

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	0.8%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Would ORIENT BIO (KRX:002630) Be Better Off With Less Debt?

May 01

Is ORIENT BIO (KRX:002630) Weighed On By Its Debt Load?

Jan 16

CEO

Jae-Jin Chang (63 yo)

no data

Permanencia

Mr. Jae-Jin Chang serves as the Chief Executive Officer of Bio Genomics, Inc. Mr. Chang serves as President, Chief Executive Officer and Chairperson of ORIENT BIO Inc. He completed graduate studies at Konk...

ORIENT BIO Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

ORIENT BIO Inc., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Inotiv, Inc. (NasdaqCM:NOTV) acquired Orient BioResource Center, Inc. from ORIENT BIO Inc. (KOSE:A002630) for $51.3 million.

Second quarter 2022 earnings released: ₩2.00 loss per share (vs ₩81.00 loss in 2Q 2021)

First quarter 2022 earnings released: EPS ₩23.00 (vs ₩4.00 loss in 1Q 2021)

Full year 2021 earnings released: ₩135 loss per share (vs ₩116 loss in FY 2020)

Would ORIENT BIO (KRX:002630) Be Better Off With Less Debt?

Third quarter 2021 earnings released: EPS ₩34.00 (vs ₩4.00 loss in 3Q 2020)

Is ORIENT BIO (KRX:002630) Weighed On By Its Debt Load?

New 90-day high: ₩1,950

New 90-day low: ₩1,230

New 90-day low: ₩1,405

Second quarter 2021 earnings released: ₩81.00 loss per share

ORIENT BIO Inc.(KOSE:A002630) dropped from S&P Global BMI Index

New 90-day high - ₩2,015

ORIENT BIO Inc. announced that it has received KRW 11.67259512 billion in funding from MDAS Inc., Orient Precision Industries Inc.

ORIENT BIO Inc. (KOSE:A002630) agreed to acquire an additional 29.74% stake in Orient Electronics Co.,Ltd. for KRW 6.7 billion.

New 90-day high - ₩785

CEO

Permanencia